Epstein-barr virus and cytomegalovirus infections cause false-positive results in IgM two-test protocol for early lyme borreliosis

Infection ◽  
1999 ◽  
Vol 27 (3) ◽  
pp. 231-231 ◽  
Author(s):  
H. A. T. Goossens ◽  
A. E. J. M. van den Bogaard ◽  
M. K. E. Nohlmans ◽  
A. E. J. M. van den Bogaard
2019 ◽  
Vol 21 (2) ◽  
pp. 18-23
Author(s):  
I A Rakityanskaya ◽  
T S Ryabova ◽  
U A Todzhibaev ◽  
A A Kalashnikov ◽  
A S Manuilov

A total of 60 patients (38 women and 22 men, 36,54±2,14 years old) with a Epstein - Barr infection were examined. The patients were divided into two groups depending on the treatment regimen: 1 group - 34 patients received ingaron therapy (10 intramuscular injections of 500000 units every other day); group 2-26 patients received valcyte (450 mg 2 times a day, by mouth, 2 months) + ingaron at the same dosage. One month after the end of antiviral therapy in the1st group, negative results of half-chain reaction were obtained only in 29,41% of patients. The combination of valcyte and ingaron in patients of the 2nd group was different and differed in the duration of the injection of ingarone: 2a group: ingaron10 injections of 500000 IU intramuscularly every other day; 2b group: ingaron 20 injections of 500000 IU intramuscularly every other day; 2c group: ingaron 10 injections of 500000 IU and 15 injections of 100000 IU intramuscularly every other day. The best result after the introduction of ingaron was obtained in 90% of patients who received the longest course of ingaron in the form of 20 injections of 500000 IU every other day in combination with valcyte. In the other groups, where the total dose of ingaron was lower, positive results were found in 60 and 66,7% of patients. A significant positive change in the number of copies of deoxyribonucleic acid Epstein - Barr virus was found in samples of saliva and the severity of clinical complaints in patients one month after the ingaron monotherapy or combination therapy (valcyte and ingaron) was completed. The best effect of treatment with ingaron is achieved in patients with chronic Epstein - Barr infection with the prolonged introduction of ingaron (at least 20 injections).


2008 ◽  
Vol 15 (5) ◽  
pp. 891-892 ◽  
Author(s):  
Mario Berth ◽  
Eugene Bosmans

ABSTRACT Immunoassay interference causing unexpected reactive results in magnetic-microparticle-based assays was detected. A systematic evaluation of Liaison Epstein-Barr virus immunoglobulin M showed that 5% of the positive results (0.4% of tested samples) could be explained by such interference. Adding chemical blocking reagents (polyvinylpyrrolidone and polyvinyl alcohol) to the assay buffers partially prevented this phenomenon.


2017 ◽  
Vol 14 (1) ◽  
Author(s):  
Samah Aly Loutfy ◽  
Maha A. Abo-Shadi ◽  
Mohamed Fawzy ◽  
Mohamed El-Wakil ◽  
Shimaa A. Metwally ◽  
...  

2021 ◽  
Vol 14 (10) ◽  
Author(s):  
Mahin Ahangar Oskouee ◽  
Jamal Sarvari ◽  
Afagh Moattari ◽  
Ahmad Habibi ◽  
Amir Taher Eftehkar Sadat

Background: Given the fact that viral infections play an important role, either directly or indirectly, in around 20 percent of human cancers, this study aimed at investigating the potential association of Epstein–Barr virus (EBV) and cytomegalovirus (CMV) infections in esophageal cancer that is the sixth most common cause of cancer-related deaths. Methods: In this case-control study, a total of 200 paraffin-embedded biopsies of cancerous and benign esophageal tissues were gathered from the biopsy bank of Imam Reza Hospital, Tabriz, Iran in 2017. All samples were first deparaffinized, and then subjected to commercial DNA extraction. The quality of extracted DNA was evaluated by amplification of the beta globulin gene. Identification of EBV and CMV DNA was performed using primers designed for the EBER region of EBV and the immediate early (IE) region of the CMV genome, respectively. Results: The mean age of the subjects in the test and control groups was 52.2 (17.1) and 59.9 (18.9), respectively. The distribution of gender (male/female) in patient and control groups was 54/46 and 53/47, respectively. Our results showed that the frequency of EBV (P < 0.001) and CMV (P < 0.001) in cancerous samples was statistically higher than control group. Moreover, in the cancerous group the rate of EBV was significantly higher in the esophageal adenocarcinomas (EAC) sample (12 out of 70) than esophageal squamous cell carcinomas (ESCC) (0 out of 30) (P = 0.016) but, in the ESCC group, 17 out of 30 subjects were positive for CMV which was significantly higher in comparison with EAC patients (1 out of 70) (P < 0.001). Conclusions: Findings indicated that EBV and CMV might be contributed to the pathogenesis of EAC and ESCC types of esophageal carcinoma, respectively, although further studies are warranted.


PEDIATRICS ◽  
1994 ◽  
Vol 94 (6) ◽  
pp. 892-894 ◽  
Author(s):  
Dorothy Levine ◽  
Rosemary Klenk ◽  
Alan Morelli ◽  
Nancy Hofreuter ◽  
Richard C. Tilton ◽  
...  

Objectives. To assess the reliability of the Monolert test, a new enzyme-linked immunosorbent assay for the diagnosis of acute infectious mononucleosis (IM). Design. A retrospective laboratory and clinical analysis of 38 children diagnosed with acute IM. Setting. A suburban pediatric practice in Connecticut. Patients. Thirty-eight children (ages 18 months to 17 years) who were diagnosed with acute IM using the Monolert test during the period October 1992 to August 1993. Results. Eighty-three percent of these children had no evidence of Epstein-Barr virus infection on subsequent investigation. The false positive results of the Monolert test could not be explained on the basis of elevated antibody titers to either cytomegalovirus or Borrelia burgdorferi. Conclusion. Monolert is a poor screening test and is of little apparent value as a diagnostic test for acute Epstein-Barr virus infection in pediatric patients.


2011 ◽  
Vol 70 (5) ◽  
pp. e27-e28 ◽  
Author(s):  
Robert Philibert ◽  
Kristin Caspers ◽  
Steven R.H. Beach ◽  
Marian J. Bakermans-Kranenburg ◽  
Marinus H. van IJzendoorn

Sign in / Sign up

Export Citation Format

Share Document